fashion -WSS

fashion

author：focus 2025-09-27 22:18:10 - browse：23

A judge ruled that Welsh Carson won't have to face antitrust allegations about its anesthesiology practice. Adobe

Welsh, Carson, Anderson & Stowe has wiggled out of the grasp of the Federal Trade Commission, but the private equity firm’s anesthesia company, U.S. Anesthesia Partners, still must face the agency’s antitrust case, a judge ruled last week.

The FTC alleged last year that the anesthesiology network monopolized markets in Texas to drive up prices, but took the unusual step of attaching Welsh Carson as a defendant with USAP. Dismissing Welsh Carson from the case was a victory for the private equity firm and, more broadly, other firms worried that the Biden administration would try to hold them responsible for anything their portfolio companies do.

But the allegations against USAP didn’t disappear, which will keep up scrutiny on companies that have made a push to acquire numerous physician groups.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily market-moving biopharma analysis — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： NIH study of ME/CFS points to clear biological hallmarks

WSS

Neurocrine Biosciences, biotech based in San Diego, joins PhRMA

STAT readers on older presidents, polypills, Medicare, and more

STAT readers on older presidents, polypills, Medicare, and more

Shifting the focus from loneliness to social health

Neurocrine Biosciences, biotech based in San Diego, joins PhRMA

Alabama IVF ruling threatens families facing fatal genetic disease

hotspot

fashion

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily market-moving biopharma analysis — by subscribing to STAT+.

Wikipedia

How one medical school became remarkably diverse

Antivenom research: Lessons from HIV applied in search for universal antidote

Duchenne breakthrough therapy leaves behind pioneering families

Ionis drug prevents swelling attacks due to hereditary angioedema

Walensky prepares to leave CDC — and Congress — behind

Community Health Systems hospitals under DOJ investigation

Medicare details structure of new drug price negotiation program

6 phony surgeries that take placebo to the extreme

Medicare proposal to cover medical devices draws a mixed reaction

NIH study of ME/CFS points to clear biological hallmarks

knowledge

The Readout: Abbvie and Humira, CRISPR in utero, Annovis Bio

How to increase colonoscopy rates? Looks like an AI can help

NIH documents show early flaws of $1.6 billion long Covid program

ASCO: AstraZeneca says CAR

ASCO: Palliative care found as helpful given virtually as in person

The Readout: Abbvie and Humira, CRISPR in utero, Annovis Bio

focus

entertainment

focus

focus